Recent advances in cancer stem/progenitor cell research: Therapeutic implications for overcoming resistance to the most aggressive cancers: Stem Cells Review Series

Journal of Cellular and Molecular Medicine

Volumn 11, Issue 5, 2007, Pages 981-1011

  Mimeault, M ^a,b   Hauke, R ^a,b   Mehta, P P ^a,b   Batra, S K ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cancer progenitor cells; Chemotherapeutic treatments; Drug resistance mechanisms targeting therapies; Endothelial progenitor cells; Oncogenic signalling

Indexed keywords

ANIMAL; ARTICLE; CANCER STEM CELL; CLASSIFICATION; DISEASE COURSE; DRUG RESISTANCE; HUMAN; NEOPLASM; PATHOLOGY;

ANIMALS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS;

ERINACEIDAE;

EID: 35648999534     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2007.00088.x     Document Type: Article

References (242)

1. Lowenberg B, Griffin JD, Tallman MS. Acute myeloid leukemia and acute promyelocytic leukemia. Hematology Am Soc Hematol Educ. Program 2003 82 101.
2. Mimeault M, Brand RE, Sasson AA, Batra SK. Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies. Pancreas. 2005 31 : 301 16.
3. Mimeault M, Batra SK. Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis. 2006 27 : 1 22.
4. Lock-Andersen J, Horn J, Sjostrand H. Prognosis after sentinel node biopsy in malignant melanoma. Ugeskr Laeger. 2006 168 : 2457 62.
5. Shiraishi J, Abe H, Li F, Engelmann R, MacMahon H, Doi K. Computer-aided diagnosis for the detection and classification of lung cancers on chest radiographs ROC analysis of radiologists performance. Acad Radiol. 2006 13 : 995 1003.
6. Chatterton K, Ray E, O'Brien TS. Fluorescence diagnosis of bladder cancer. Br J Nurs. 2006 8 15 : 595 7.
7. Alexander A, Murtha A, Abdulkarim B, Mehta V, Wheatley M, Murray B, Riauka T, Hanson J, Fulton D, McEwan A, Roa W. Prognostic significance of serial magnetic resonance spectroscopies over the course of radiation therapy for patients with malignant glioma. Clin Invest Med 2006 29 : 301 11.
8. Calza S, Hall P, Auer G, Bjohle J, Klaar S, Kronenwett U, Liu ET, Miller L, Ploner A, Smeds J, Bergh J, Pawitan Y. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res. 2006 8 : R34.
9. Petignat P, du Bois A., Bruchim I, Fink D, Provencher DM. Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer? Crit Rev Oncol Hematol. 2006 62 : 137 47.
10. MacDonald TJ, Rood BR, Santi MR, Vezina G, Bingaman K, Cogen PH, Packer RJ. Advances in the diagnosis, molecular genetics, and treatment of pediatric embryonal CNS tumors. Oncologist. 2003 8 : 174 86.
11. Takei H, Bhattacharjee MB, Rivera A, Dancer Y, Powell SZ. New immunohistochemical markers in the evaluation of central nervous system tumors: a review of 7 selected adult and pediatric brain tumors. Arch Pathol Lab Med. 2007 131 : 234 41.
12. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature. 2007 445 : 851 7.
13. Mimeault M, Batra SK. Recent advances on the significance of stem cells in tissue regeneration and cancer therapies. Stem Cells. 2006 24 : 2319 45.
14. Lacroix M. Significance, detection and markers of disseminated breast cancer cells. Endocr Relat Cancer. 2006 13 : 1033 67.
15. Baehring JM. An update on oligodendroglial neo-plasms. Curr Opin Neurol. 2005 18 : 639 44.
16. Mimeault M, Hauke R, Batra SK. Recent advances on the molecular mechanisms involved in drug-resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther. 2007 82 : 252 64.
17. Sorscher SM. Biological therapy update in colorectal cancer. Expert Opin Biol Ther. 2007 7 : 509 19.
18. Brawley OW, Kramer BS. Cancer screening in theory and in practice. J Clin Oncol. 2005 23 : 293 300.
19. van der Merwe DE, Oikonomopoulou K, Marshall J, Diamandis EP. Mass spectrometry: uncovering the cancer proteome for diagnostics. Adv Cancer Res. 2006 96 : 23 50.
20. Clarke NW. Management of the spectrum of hormone refractory prostate cancer. Eur Urol. 2006 50 : 428 38.
21. Tallman MS. Treatment of relapsed or refractory acute promyelocytic leukemia. Best Pract Res Clin Haematol. 2007 20 : 57 65.
22. Zhou GB, Zhang J, Wang ZY, Chen SJ, Chen Z. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide:a paradigm of synergistic molecular targeting therapy. Philos Trans R Soc Lond B Biol Sci. 2007 362 : 959 71.
23. Zheng X, Seshire A, Ruster B, Bug G, Beissert T, Puccetti E, Hoelzer D, Henschler R, Ruthardt M. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukaemic stem cells. Haematologica. 2007 92 : 323 31.
24. Jovanovic JV, Score J, Waghorn K, Cilloni D, Gottardi E, Metzgeroth G, Erben P, Popp H, Walz C, Hochhaus A, Roche-Lestienne C, Preudhomme C, Solomon E, Apperley J, Rondoni M, Ottaviani E, Martinelli G, Brito-Babapulle F, Saglio G, Hehlmann R, Cross NC, Reiter A, Grimwade D. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA positive chronic eosinophilic leukemia. Blood. 2007 109 : 4635 40.
25. Pantel K, Woelfle U. Micrometastasis in breast cancer and other solid tumors. J Biol Regul Homeost Agents. 2004 18 : 120 5.
26. Milas L, Raju U, Liao Z, Ajani J. Targeting molecular determinants of tumor chemo-radioresistance. Semin Oncol. 2005 32 : S78 81.
27. Mauro MJ. Defining and managing imatinib resistance. Hematology Am Soc Hematol Educ Program. 2006 219 25.
28. Mughal T, Goldman JM. Optimal management of patients with newly diagnosed chronic phase chronic myeloid leukemia in 2007. Clin Lymphoma Myeloma. 2007 7 : S95 101.
29. Ceschel S, Casotto V, Valsecchi MG, Tamaro P, Jankovic M, Hanau G, Fossati F, Pillon M, Rondelli R, Sandri A, Silvestri D, Haupt R, Cuttini M. Survival after relapse in children with solid tumors:a follow-up study from the Italian off-therapy registry. Pediatr Blood Cancer. 2006 47 : 560 6.
30. Rosell R, Cecere F, Cognetti F, Cuello M, Sanchez JM, Taron M, Reguart N, Jablons D. Future directions in the second-line treatment of non-small cell lung cancer. Semin Oncol. 2006 33 : S45 51.
31. Sato M, Shames DS, Gazdar AF, Minna JD. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol. 2007 2 : 327 43.
32. Goldman J, Gordon M. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leuk Lymphoma. 2006 47 : 1 7.
33. Copland M, Jorgensen HG, Holyoake TL. Evolving molecular therapy for chronic myeloid leukaemia-are we on target? Hematology. 2005 10 : 349 59.
34. Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, Barow M, Mountford JC, Holyoake TL. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006 107 : 4532 9.
35. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005 5 : 275 84.
36. Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov. 2006 5 : 997 1014.
37. Rubin LL, de Sauvage FJ. Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov. 2006 5 : 1026 33.
38. Roberg K, Jonsson AC, Grenman R, Norberg-Spaak L. Radiotherapy response in oral squamous carcinoma cell lines:Evaluation of apoptotic proteins as prognostic factors. Head Neck. 2007 29 : 325 34.
39. Mimeault M, Batra S. Interplay of distinct growth factors during epithelial-mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies. Ann Oncol. 2007 18 : 1605 19.
40. Mimeault M, Batra SK. Functions of tumorigenic and migrating cancer progenitor cells in cancer progression and metastasis and their therapeutic implications. Cancer Metastasis Rev. 2007 26 : 203 14.
41. Nicolis SK. Cancer stem cells and "stemness" genes in neuro-oncology. Neurobiol Dis. 2007 25 : 217 29.
42. Fodde R, Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol. 2007 19 : 150 8.
43. Li XN, Shu Q, Su JM, Adesina AM, Wong KK, Perlaky L, Antalffy BA, Blaney SM, Lau CC. Differential expression of survivin splice isoforms in medulloblastomas. Neuropathol Appl Neurobiol. 2007 33 : 67 76.
44. Blanco-Aparicio C, Renner O, Leal JF, Carnero A. PTEN, more than the AKT pahway. Carcinogenesis. 2007 28 : 1379 86.
45. Fuster JJ, Sanz-Gonzalez SM, Moll UM, Andres V. Classic and novel roles of p53: prospects for anticancer therapy. Trends Mol Med. 2007 13 : 192 9.
46. de Jonge-Peeters SD, Kuipers F, de Vries EG, Vellenga E. ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Crit Rev Oncol Hematol. 2007 62 : 214 26.
47. Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene. 2004 23 : 7274 82.
48. Sell S. Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol. 2004 51 : 1 28.
49. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion:migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer. 2005 5 : 744 9.
50. Miller SJ, Lavker RM, Sun TT. Interpreting epithelial cancer biology in the context of stem cells: tumor properties and therapeutic implications. Biochim Biophys Acta. 2005 1756 : 25 52.
51. Li L, Neaves WB. Normal stem cells and cancer stem cells:the niche matters. Cancer Res. 2006 66 : 4553 7.
52. Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. Nat Rev Cancer. 2006 6 : 425 36.
53. Massard C, Deutsch E, Soria JC. Tumour stem cell-targeted treatment:elimination or differentiation. Ann Oncol. 2006 17 : 1620 4.
54. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA, Brenner MK. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA. 2004 101 : 14228 33.
55. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005 434 : 843 50.
56. Woodward WA, Chen MS, Behbod F, Rosen JM. On mammary stem cells. J Cell Sci. 2005 118 : 3585 94.
57. Galmozzi E, Facchetti F, La Porta CA. Cancer stem cells and therapeutic perspectives. Curr Med Chem. 2006 13 : 603 7.
58. Rizo A, Vellenga E, de HG, Schuringa JJ. Signaling pathways in self-renewing hematopoietic and leukaemic stem cells:do all stem cells need a niche Hum Mol Genet. 2006 15 : R210 9.
59. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea-a paradigm shift. Cancer Res. 2006 66 : 1883 90.
60. Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW, Suri P, Wicha MS. Hedgehog sig-nalling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 2006 66 : 6063 71.
61. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepa-tocellular carcinoma. Semin Liver Dis. 2007 27 : 55 76.
62. Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature. 2004 432 : 324 31.
63. Bapat SA, Mali AM, Koppikar CB, Kurrey NK. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res. 2005 65 : 3025 9.
64. Tso CL, Shintaku P, Chen J, Liu Q, Liu J, Chen Z, Yoshimoto K, Mischel PS, Cloughesy TF, Liau LM, Nelson SF. Primary glioblastomas express mes-enchymal stem-like properties. Mol Cancer Res. 2006 4 : 607 19.
65. Tan BT, Park CY, Ailles LE, Weissman IL. The cancer stem cell hypothesis: a work in progress. Lab Invest. 2006 86 : 1203 7.
66. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003 63 : 5821 8.
67. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature. 2004 432 : 396 401.
68. Al-Hajj M, Wicha MS, ito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003 100 : 3983 8.
69. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukaemic stem cell classes that differ in self-renewal capacity. Nat Immunol. 2004 5 : 738 43.
70. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE, Herlyn M. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005 65 : 9328 37.
71. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005 65 : 10946 51.
72. Yuan X, Curtin J, Xiong Y, Liu G, Waschsmann-Hogiu S, Farkas DL, Black KL, Yu JS. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene. 2004 23 : 9392 400.
73. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De VS, Fiocco R, Foroni C, Dimeco F, Vescovi A. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004 64 : 7011 21.
74. Hadnagy A, Gaboury L, Beaulieu R, Balicki D. SP analysis may be used to identify cancer stem cell populations. Exp Cell Res. 2006 312 : 3701 10.
75. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S, Pierotti MA, Daidone MG. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005 65 : 5506 11.
76. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De MR. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007 445 : 111 5.
77. Dontu G, El-Ashry D, Wicha MS. Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab. 2004 15 : 193 7.
78. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer. 2006 5 : 67.
79. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006 444 : 756 60.
80. Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, Mimori K, Barnard GF, Mori M. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells. 2006 24 : 506 13.
81. Ravandi F, Estrov Z. Eradication of leukemia stem cells as a new goal of therapy in leukemia. Clin Cancer Res. 2006 12 : 340 4.
82. Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, Kornblum HI. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA. 2003 100 : 15178 83.
83. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K, Coghlan L, Tang DG. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene. 2006 25 : 1696 708.
84. Tang DG, Patrawala L, Calhoun T, Bhatia B, Choy G, Schneider-Broussard R, Jeter C. Prostate cancer stem/progenitor cells:identification, characterization, and implications. Mol Carcinog. 2007 46 : 1 14.
85. Collins AT, Maitland NJ. Prostate cancer stem cells. Eur J Cancer. 2006 42 : 1213 8.
86. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. Identification of pancreatic cancer stem cells. Cancer Res. 2007 67 : 1030 7.
87. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA. 2007 104 : 973 8.
88. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 2007 67 : 4827 33.
89. Wang J, Guo LP, Chen LZ, Zeng YX, Lu SH. Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res. 2007 67 : 3716 24.
90. Blair A, Hogge DE, Ailles LE, Lansdorp PM, Sutherland HJ. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood. 1997 89 : 3104 12.
91. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, Smith BD, Civin CI, Jones RJ. Characterization of clonogenic multiple myeloma cells. Blood. 2004 103 : 2332 6.
92. Taylor MD, Poppleton H, Fuller C, Su X, Liu Y, Jensen P, Magdaleno S, Dalton J, Calabrese C, Board J, Macdonald T, Rutka J, Guha A, Gajjar A, Curran T, Gilbertson RJ. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell. 2005 8 : 323 35.
93. Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK, Trosko JE. Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis. 2005 26 : 495 502.
94. Wulf GG, Wang RY, Kuehnle I, Weidner D, Marini F, Brenner MK, Andreeff M, Goodell MA. A leukaemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood. 2001 98 : 1166 73.
95. Scharenberg CW, Harkey MA, Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood. 2002 99 : 507 12.
96. Setoguchi T, Taga T, Kondo T. Cancer stem cells persist in many cancer cell lines. Cell Cycle. 2004 3 : 414 5.
97. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA. 2004 101 : 781 6.
98. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc Natl Acad Sci USA. 2006 103 : 11154 9.
99. Haraguchi N, Inoue H, Tanaka F, Mimori K, Utsunomiya T, Sasaki A, Mori M. Cancer stem cells in human gastrointestinal cancers. Hum Cell. 2006 19 : 24 9.
100. Seigel GM, Campbell LM, Narayan M, Gonzalez-Fernandez F. Cancer stem cell characteristics in retinoblastoma. Mol Vis. 2005 11 : 729 37.
101. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2 +and ABCG2- cancer cells are similarly tumorigenic. Cancer Res. 2005 65 : 6207 19.
102. Chen JS, Pardo FS, Wang-Rodriguez J, Chu TS, Lopez JP, Aguilera J, Altuna X, Weisman RA, Ongkeko WM. EGFR regulates the side population in head and neck squamous cell carcinoma. Laryngoscope. 2006 116 : 401 6.
103. Grichnik JM, Burch JA, Schulteis RD, Shan S, Liu J, Darrow TL, Vervaert CE, Seigler HF. Melanoma, a tumor based on a mutant stem cell? J Invest Dermatol. 2006 126 : 142 53.
104. Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A, Nakauchi H, Taniguchi H. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology. 2006 44 : 240 51.
105. Mitsutake N, Iwao A, Nagai K, Namba H, Ohtsuru A, Saenko V, Yamashita S. Characterization of side population in thyroid cancer cell lines:cancer stem-like cells are enriched partly but not exclusively. Endocrinology. 2007 148 : 1797 803.
106. Miyamoto T, Weissman IL, Akashi K. AML1/ETO-expressing nonleukemic stem cells in acute myeloge-nous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci USA. 2000 97 : 7521 6.
107. Cozzio A, Passegue E, Ayton PM, Karsunky H, Cleary ML, Weissman IL. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev. 2003 17 : 3029 35.
108. Jamieson CH, Weissman IL, Passegue E. Chronic versus acute myelogenous leukemia: a question of self-renewal. Cancer Cell. 2004 6 : 531 3.
109. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating A, Sawyers CL, Weissman IL. Granulocyte-macrophage progenitors as candidate leukaemic stem cells in blast-crisis CML. N Engl J Med. 2004 351 : 657 67.
110. Huntly BJ, Shigematsu H, Deguchi K, Lee BH, Mizuno S, Duclos N, Rowan R, Amaral S, Curley D, Williams IR, Akashi K, Gilliland DG. MOZ-TIF2, but not BCR-ABL, confers properties of leukaemic stem cells to committed murine hematopoietic progenitors. Cancer Cell. 2004 6 : 587 96.
111. Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC, Chintagumpala M, Adesina A, Ashley DM, Kellie SJ, Taylor MD, Curran T, Gajjar A, Gilbertson RJ. Genomics identifies medul-loblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol. 2006 24 : 1924 31.
112. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med. 2007 58 : 267 84.
113. Chen L, Shen R, Ye Y, Pu XA, Liu X, Duan W, Wen J, Zimmerer J, Wang Y, Liu Y, Lasky LC, Heerema NA, Perrotti D, Ozato K, Kuramochi-Miyagawa S, Nakano T, Yates AJ, Carson Iii WE, Lin H, Barsky SH, Gao JX. Precancerous stem cells have the potential for both benign and malignant differentiation. PLoS ONE. 2007 2 : e293.
114. Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer. 2003 3 : 685 94.
115. Mackall CL, Meltzer PS, Helman LJ. Focus on sarcomas. Cancer Cell. 2002 2 : 175 8.
116. Tataria M, Quarto N, Longaker MT, Sylvester KG. Absence of the p53 tumor suppressor gene promotes osteogenesis in mesenchymal stem cells. J Pediatr Surg. 2006 41 : 624 32.
117. Thomas D, Kansara M. Epigenetic modifications in osteogenic differentiation and transformation. J Cell Biochem. 2006 98 : 757 69.
118. Tiffin N, Williams RD, Shipley J, Pritchard-Jones K. PAX7 expression in embryonal rhabdomyosarco-ma suggests an origin in muscle satellite cells. Br J Cancer. 2003 89 : 327 32.
119. Tostar U, Malm J, Meis-Kindblom JM, Kindblom LG, Toftgard R, Unden AB. Deregulation of the hedgehog signalling pathway: a possible role for the PTCH and SUFU genes in human rhabdomyoma and rhabdomyosarcoma development. J Pathol. 2006 208 : 17 25.
120. McDonald SA, Preston SL, Lovell MJ, Wright NA, Jankowski JA. Mechanisms of disease: from stem cells to colorectal cancer. Nat Clin Pract Gastroenterol Hepatol. 2006 3 : 267 74.
121. Hoebeeck J, Vandesompele J, Nilsson H, De PK, Van RN, De SE, Yigit N, De PA, Laureys G, Pahlman S, Speleman F. The von Hippel-Lindau tumor suppressor gene expression level has prognostic value in neuroblastoma. Int J Cancer. 2006 119 : 624 9.
122. Mannelli M, Simi L, Gagliano MS, Opocher G, Ercolino T, Becherini L, Parenti G. Genetics and biology of pheochromocytoma. Exp Clin Endocrinol Diabetes. 2007 115 : 160 5.
123. Park DM, Zhuang Z, Chen L, Szerlip N, Maric I, Li J, Sohn T, Kim SH, Lubensky IA, Vortmeyer AO, Rodgers GP, Oldfield EH, Lonser RR. von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells. PLoS Med. 2007 4 : e60.
124. Lugus JJ, Park C, Choi K. Developmental relationship between hematopoietic and endothelial cells. Immunol Res. 2005 32 : 57 74.
125. Chan CC, Collins AB, Chew EY. Molecular pathology of eyes with von Hippel-Lindau (VHL) Disease: a review. Retina. 2007 27 : 1 7.
126. Sklar CA. Childhood brain tumors. J Pediatr Endocrinol Metab. 2002 2 : 669 73.
127. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, Allen JC, Zagzag D, Olson JM, Curran T, Wetmore C, Biegel JA, Poggio T, Mukherjee S, Rifkin R, Califano A, Stolovitzky G, Louis DN, Mesirov JP, Lander ES, Golub TR. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002 415 : 436 42.
128. Nakagawara A, Ohira M. Comprehensive genomics linking between neural development and cancer: neu-roblastoma as a model. Cancer Lett. 2004 204 : 213 24.
129. Walton JD, Kattan DR, Thomas SK, Spengler BA, Guo HF, Biedler JL, Cheung NK, Ross RA. Characteristics of stem cells from human neuroblas-toma cell lines and in tumors. Neoplasia. 2004 6 : 838 45.
130. Ross RA, Spengler BA. Human neuroblastoma stem cells. Semin Cancer Biol. 2007 17 : 241 7.
131. Rafii S, Lyden D, Benezra R, Hattori K, and Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer. 2002 2 : 826 35.
132. Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med. 2005 9 : 777 94.
133. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: A novel tumor-promoting cell type. Cell Cycle. 2006 5 : 1597 601.
134. Kopp HG, Ramos CA, Rafii S. Contribution of endothelial progenitors and proangiogenic hematopoietic cells to vascularization of tumor and ischemic tissue. Curr Opin Hematol. 2006 13 : 175 81.
135. Ganss R. Tumor stroma fosters neovascularization by recruitment of progenitor cells into the tumor bed. J Cell Mol Med. 2006 10 : 857 65.
136. Moreira IS, Fernandes PA, Ramos MJ. Vascular endothelial growth factor (VEGF) inhibition-a critical review. Anticancer Agents Med Chem. 2007 7 : 223 45.
137. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S. Impaired recruitment of bone-marrow-derived endothe-lial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001 7 : 1194 201.
138. Peters BA, Diaz LA, Polyak K, Meszler L, Romans K, Guinan EC, Antin JH, Myerson D, Hamilton SR, Vogelstein B, Kinzler KW, Lengauer C. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med. 2005 11 : 261 2.
139. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005 438 : 820 7.
140. Davidoff AM, Ng CY, Brown P, Leary MA, Spurbeck WW, Zhou J, Horwitz E, Vanin EF, Nienhuis AW. Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin Cancer Res. 2001 7 : 2870 9.
141. Dome B, Timar J, Dobos J, Meszaros L, Raso E, Paku S, Kenessey I, Ostoros G, Magyar M, Ladanyi A, Bogos K, Tovari J. Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res. 2006 66 : 7341 7.
142. Hammerling GJ, Ganss R. Vascular integration of endothelial progenitors during multistep tumor progression. Cell Cycle. 2006 5 : 509 11.
143. Spring H, Schuler T, Arnold B, Hammerling GJ, Ganss R. Chemokines direct endothelial progenitors into tumor neovessels. Proc Natl Acad Sci USA. 2005 102 : 18111 6.
144. Santarelli JG, Udani V, Yung YC, Cheshier S, Wagers A, Brekken RA, Weissman I, Tse V. Incorporation of bone marrow-derived Flk-1-expressing CD34+ cells in the endothelium of tumor vessels in the mouse brain. Neurosurgery. 2006 59 : 374 82.
145. Hilbe W, Dirnhofer S, Oberwasserlechner F, Schmid T, Gunsilius E, Hilbe G, Woll E, Kahler CM. CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J Clin Pathol. 2004 57 : 965 9.
146. da Silva ML, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all postnatal organs and tissues. J Cell Sci. 2006 119 : 2204 13.
147. Zengin E, Chalajour F, Gehling UM, Ito WD, Treede H, Lauke H, Weil J, Reichenspurner H, Kilic N, Ergun S. Vascular wall resident progenitor cells: a source for postnatal vasculogenesis. Development. 2006 133 : 1543 51.
148. Bruno S, Bussolati B, Grange C, Collino F, Graziano ME, Ferrando U, Camussi G. CD133 +renal progenitor cells contribute to tumor angiogene-sis. Am J Pathol. 2006 169 : 2223 35.
149. Sun B, Zhang S, Ni C, Zhang D, Liu Y, Zhang W, Zhao X, Zhao C, Shi M. Correlation between melanoma angiogenesis and the mesenchymal stem cells and endothelial progenitor cells derived from bone marrow. Stem Cells Dev. 2005 14 : 292 8.
150. Sell S. Leukemia:stem cells, maturation arrest, and differentiation therapy. Stem Cell Rev. 2005 1 : 197 205.
151. Tokar EJ, Ancrile BB, Cunha GR, Webber MM. Stem/progenitor and intermediate cell types and the origin of human prostate cancer. Differentiation. 2005 73 : 463 73.
152. Villadsen R. In search of a stem cell hierarchy in the human breast and its relevance to breast cancer evolution. APMIS. 2005 113 : 903 21.
153. Morrow M, Samanta A, Kioussis D, Brady HJ, Williams O. TEL-AML1 preleukemic activity requires the DNA binding domain of AML1 and the dimerization and corepressor binding domains of TEL. Oncogene. 2007 26 : 4404 14.
154. Martinez-Jaramillo G, Vela-Ojeda J, Sanchez-Valle E, Montesinos JJ, Mayani H. in vitro functional alterations in the hematopoietic system of adult patients with acute lymphoblastic leukemia. Leuk Res. 2007 31 : 83 9.
155. Zhang M, Rosen JM. Stem cells in the etiology and treatment of cancer. Curr Opin Genet Dev. 2006 16 : 60 4.
156. Birnbaum D, Bertucci F, Ginestier C, Tagett R, Jacquemier J, Charafe-Jauffret E. Basal and lumi-nal breast cancers:basic or luminous? (review). Int J Oncol. 2004 25 : 249 58.
157. Eberhart CG. In search of the medulloblast: neural stem cells and embryonal brain tumors. Neurosurg. Clin N Am. 2007 18 : 59-ix.
158. Zindy F, Uziel T, Ayrault O, Calabrese C, Valentine M, Rehg JE, Gilbertson RJ, Sherr CJ, Roussel MF. Genetic alterations in mouse medulloblastomas and generation of tumors de novo from primary cerebel-lar granule neuron precursors. Cancer Res. 2007 67 : 2676 84.
159. Cobaleda C, Gutierrez-Cianca N, Perez-Losada J, Flores T, Garcia-Sanz R, Gonzalez M, Sanchez-Garcia I. A primitive hematopoietic cell is the target for the leukaemic transformation in human philadelphia-positive acute lymphoblastic leukemia. Blood. 2000 95 : 1007 13.
160. Nakagawa R, Soh JW, Michie AM. Subversion of protein kinase C alpha signaling in hematopoietic progenitor cells results in the generation of a B-cell chronic lymphocytic leukemia-like population in vivo. Cancer Res. 2006 66 : 527 34.
161. Reilly JT. Class III receptor tyrosine kinases: role in leukaemogenesis. Br J Haematol. 2002 116 : 744 57.
162. Moore MA. Converging pathways in leukemogenesis and stem cell self-renewal. Exp Hematol. 2005 33 : 719 37.
163. Ysebaert L, Chicanne G, Demur C, De TF, Prade-Houdellier N, Ruidavets JB, Mansat-De M, V, Rigal-Huguet F, Laurent G, Payrastre B, Manenti S, Racaud-Sultan C. Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia. 2006 20 : 1211 6.
164. Sengupta A, Banerjee D, Chandra S, Banerji SK, Ghosh R, Roy R, Banerjee S. Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression. Leukemia. 2007 21 : 949 55.
165. Frankfurt O, Tallman MS. Growth factors in leukemia. J Natl Compr Canc Netw. 2007 5 : 203 15.
166. Bhatia M, Bonnet D, Murdoch B, Gan OI, Dick JE. A newly discovered class of human hematopoietic cells with SCID-repopulating activity. Nat Med. 1998 4 : 1038 45.
167. Zanjani ED, Meida-Porada G, Livingston AG, Zeng H, Ogawa M. Reversible expression of CD34 by adult human bone marrow long-term engrafting hematopoi-etic stem cells. Exp Hematol. 2003 31 : 406 12.
168. Gupta P, Gurudutta GU, Verma YK, Kishore V, Gulati S, Sharma RK, Chandra R, Saluja D. PU.1: An ETS family transcription factor that regulates leukemogenesis besides normal hematopoiesis. Stem Cells Dev. 2006 15 : 609 17.
169. Carella C, Bonten J, Rehg J, Grosveld GC. MN1-TEL, the product of the t(12;22) in human myeloid leukemia, immortalizes murine myeloid cells and causes myeloid malignancy in mice. Leukemia. 2006 20 : 1582 92.
170. Nishida S, Hosen N, Shirakata T, Kanato K, Yanagihara M, Nakatsuka S, Hoshida Y, Nakazawa T, Harada Y, Tatsumi N, Tsuboi A, Kawakami M, Oka Y, Oji Y, Aozasa K, Kawase I, Sugiyama H. AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1. Blood. 2006 107 : 3303 12.
171. Somervaille TC, Cleary ML. PU.1 and Junb: suppressing the formation of acute myeloid leukemia stem cells. Cancer Cell. 2006 10 : 456 7.
172. Moore MA, Dorn DC, Schuringa JJ, Chung KY, Morrone G. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells. Exp Hematol. 2007 35 : 105 16.
173. Kosmider O, Denis N, Lacout C, Vainchenker W, Dubreuil P, Moreau-Gachelin F. Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during ery-throleukemia in mice. Cancer Cell. 2005 8 : 467 78.
174. Primo D, Flores J, Quijano S, Sanchez ML, Sarasquete ME, del Pino-Montes J, Gaarder PI, Gonzalez M, Orfao A. Impact of BCR/ABL gene expression on the proliferative rate of different sub-populations of haematopoietic cells in chronic myeloid leukaemia. Br J Haematol. 2006 135 : 43 51.
175. Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S. Targeting multiple kinase pathways in leukaemic progenitors and stem cells is essential for improved treatment of Ph +leukemia in mice. Proc Natl Acad Sci USA. 2006 103 : 16870 5.
176. Asahara T, Kawamoto A. Endothelial progenitor cells for postnatal vasculogenesis. Am J Physiol Cell Physiol. 2004 287 : C572 9.
177. Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW, Ghivizzani SC, Ignatova TN, Steindler DA. Stem-like cells in bone sarcomas:impli-cations for tumorigenesis. Neoplasia. 2005 7 : 967 76.
178. Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis MA, McElmurry RT, Bell S, Xia L, Zhou N, Riddle M, Schroeder TM, Westendorf JJ, McIvor RS, Hogendoorn PC, Szuhai K, Oseth L, Hirsch B, Yant SR, Kay MA, Peister A, Prockop DJ, Fibbe WE, Blazar BR. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells. 2007 25 : 371 9.
179. Riggi N, Cironi L, Provero P, Suva ML, Kaloulis K, Garcia-Echeverria C, Hoffmann F, Trumpp A, Stamenkovic I. Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res. 2005 65 : 11459 68.
180. Holland EC, Li Y, Celestino J, Dai C, Schaefer L, Sawaya RA, Fuller GN. Astrocytes give rise to oligo-dendrogliomas and astrocytomas after gene transfer of polyoma virus middle T antigen in vivo. Am J Pathol. 2000 157 : 1031 7.
181. Sanai N, varez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N Engl J Med. 2005 353 : 811 22.
182. Lubensky IA, Vortmeyer AO, Kim S, Lonser RR, Park DM, Ikejiri B, Li J, Okamoto H, Walbridge S, Ryschkewitsch C, Major E, Oldfield EH, Zhuang Z. Identification of tumor precursor cells in the brains of primates with radiation-induced de novo glioblastoma multiforme. Cell Cycle. 2006 5 : 452 6.
183. Dellovade T, Romer JT, Curran T, Rubin LL. The hedgehog pathway and neurological disorders. Annu Rev Neurosci. 2006 29 : 539 63.
184. Sharma MK, Mansur DB, Reifenberger G, Perry A, Leonard JR, Aldape KD, Albin MG, Emnett RJ, Loeser S, Watson MA, Nagarajan R, Gutmann DH. Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Res. 2007 67 : 890 900.
185. Zhu Y, Guignard F, Zhao D, Liu L, Burns DK, Mason RP, Messing A, Parada LF. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell. 2005 8 : 119 30.
186. Mao Y, Zhou L, Zhu W, Wang X, Yang G, Xie L, Mao X, Jin K. Proliferative status of tumor stem cells may be correlated with malignancy grade of human astro-cytomas. Front Biosci. 2007 12 : 2252 9.
187. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, Frank A, Bayazitov IT, Zakharenko SS, Gajjar A, Davidoff A, Gilbertson RJ. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007 11 : 69 82.
188. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U, Beier CP. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007 67 : 4010 5.
189. Gu G, Yuan J, Wills M, Kasper S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res. 2007 67 : 4807 15.
190. Liu S, Dontu G, Wicha MS. Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res. 2005 7 : 86 95.
191. Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, Isaacs JT, Berman DM, Beachy PA. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature. 2004 431 : 707 12.
192. Teuliere J, Faraldo MM, Deugnier MA, Shtutman M, Ben-Ze'ev A, Thiery JP, Glukhova MA. Targeted activation of beta-catenin signaling in basal mammary epithelial cells affects mammary development and leads to hyperplasia. Development. 2005 132 : 267 77.
193. Clarke RB, Spence K, Anderson E, Howell A, Okano H, Potten CS. A putative human breast stem cell population is enriched for steroid receptor-positive cells. Dev Biol. 2005 277 : 443 56.
194. Du Z, Podsypanina K, Huang S, McGrath A, Toneff MJ, Bogoslovskaia E, Zhang X, Moraes RC, Fluck M, Allred DC, Lewis MT, Varmus HE, Li Y. Introduction of oncogenes into mammary glands in vivo with an avian retroviral vector initiates and promotes carcinogenesis in mouse models. Proc Natl Acad Sci USA. 2006 103 : 17396 401.
195. Tang P, Wang X, Schiffhauer L, Wang J, Bourne P, Yang Q, Quinn A, Hajdu S. Expression patterns of ER-alpha, PR, HER-2/neu, and EGFR in different cell origin subtypes of high grade and non-high grade ductal carcinoma in situ. Ann Clin Lab Sci. 2006 36 : 137 43.
196. Moraes RC, Zhang X, Harrington N, Fung JY, Wu MF, Hilsenbeck SG, Allred DC, Lewis MT. Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasia. Development. 2007 134 : 1231 42.
197. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004 10 : 5367 74.
198. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006 19 : 264 71.
199. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006 295 : 2492 02.
200. Jumppanen M, Gruvberger-Saal S, Kauraniemi P, Tanner M, Bendahl PO, Lundin M, Krogh M, Kataja P, Borg A, Ferno M, Isola J. Basal-like phenotype is not associated with patient survival in estrogen receptor negative breast cancers. Breast Cancer Res. 2007 9 : R16.
201. Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, Borresen-Dale AL. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics. 2006 7 : 127.
202. Potemski P, Kusinska R, Watala C, Pluciennik E, Bednarek AK, Kordek R. Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology. 2005 69 : 478 85.
203. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007 109 : 25 32.
204. Asselin-Labat ML, Shackleton M, Stingl J, Vaillant F, Forrest NC, Eaves CJ, Visvader JE, Lindeman GJ. Steroid hormone receptor status of mouse mammary stem cells. J Natl Cancer Inst 2006 98 : 1011 4.
205. Sleeman KE, Kendrick H, Robertson D, Isacke CM, Ashworth A, Smalley MJ. Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland. J Cell Biol. 2007 176 : 19 26.
206. Fujita N, Jaye DL, Kajita M, Geigerman C, Moreno CS, Wade PA. MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell. 2003 113 : 207 19.
207. Kurbel S. Selective reduction of estrogen receptor (ER) positive breast cancer occurrence by estrogen receptor modulators supports etiological distinction between ER positive and ER negative breast cancers. Med Hypotheses. 2005 64 : 1182 7.
208. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA. 1998 95 : 15665 70.
209. Kim M, Turnquist H, Jackson J, Sgagias M, Yan Y, Gong M, Dean M, Sharp JG, Cowan K. The mul-tidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res. 2002 8 : 22 8.
210. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic ade-nocarcinoma cells. Oncogene. 2004 23 : 465 73.
211. Kornblau SM, Qiu YH, Bekele BN, Cade JS, Zhou X, Harris D, Jackson CE, Estrov Z, Andreeff M. Studying the right cell in acute myelogenous leukemia:dynamic changes of apoptosis and signal transduction pathway protein expression in chemotherapy resistant ex-vivo selected "survivor cells". Cell Cycle. 2006 5 : 2769 77.
212. Chen MS, Woodward WA, Behbod F, Peddibhotla S, Alfaro MP, Buchholz TA, Rosen JM. Wnt/beta-catenin mediates radiation resistance of Sca1+ pro-genitors in an immortalized mammary gland cell line. J Cell Sci. 2007 120 : 468 77.
213. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44 +breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006 98 : 1777 85.
214. Yanai K, Nagai S, Wada J, Yamanaka N, Nakamura M, Torata N, Noshiro H, Tsuneyoshi M, Tanaka M, Katano M. Hedgehog signaling pathway is a possible therapeutic target for gastric cancer. J Surg Oncol. 2007 95 : 55 62.
215. Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li YM, Eberhart CG. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 2006 66 : 7445 52.
216. Mimeault M, Johansson SL, Venkatraman G, Moore E, Henichart JP, Depreux P, Lin MF, Batra SK. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. Mol Cancer Ther. 2007 6 : 967 78.
217. Lou H, Dean M. Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene. 2007 26 : 1357 60.
218. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr., Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005 353 : 1673 84.
219. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005 353 : 1659 72.
220. Zhang Q, Chen G, Liu X, Qian Q. Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy. Cell Res. 2007 17 : 89 99.
221. Sano T, Kagawa M, Okuno M, Ishibashi N, Hashimoto M, Yamamoto M, Suzuki R, Kohno H, Matsushima-Nishiwaki R, Takano Y, Tsurumi H, Kojima S, Friedman SL, Moriwaki H, Tanaka T. Prevention of rat hepatocarcinogenesis by acyclic retinoid is accompanied by reduction in emergence of both TGF-alpha-expressing oval-like cells and activated hepatic stellate cells. Nutr Cancer. 2005 51 : 197 206.
222. Ringden O. Immunotherapy by allogeneic stem cell transplantation. Adv Cancer Res. 2007 97C : 25 60.
223. Avramova B, Jordanova M, Michailov G, Konstantinov D, Christosova I, Bobev D. Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation in patients with poor-prognosis solid tumors - Bulgarian experience. J BUON. 2006 11 : 433 48.
224. Mimeault M, Hauke R, Batra SK. Stem cells:A revolution in therapeutics-Recent advances on the stem cell biology and their therapeutic applications in regenerative medicine and cancer therapies. Clin Pharm Ther. 2007 82 : 252 64.
225. Bickenbach K, Wilcox R, Veerapong J, Kindler HL, Posner MC, Noffsinger A, Roggin KK. A review of resistance patterns and phenotypic changes in gastrointestinal stromal tumors following imatinib mesylate therapy. J Gastrointest Surg. 2007 11 : 758 66.
226. Burger H, Nooter K. Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib. Cell Cycle. 2004 3 : 1502 05.
227. Schenone S, Manetti F, Botta M. Last findings on dual inhibitors of abl and SRC tyrosine-kinases. Mini Rev Med Chem. 2007 7 : 191 201.
228. Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A, Eaves C. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia. 2007 21 : 926 35.
229. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, Talpaz M. BCR-ABL independence and LYN kinase overexpression in chronic myeloge-nous leukemia cells selected for resistance to STI571. Blood. 2003 101 : 690 8.
230. Angstreich GR, Matsui W, Huff CA, Vala MS, Barber J, Hawkins AL, Griffin CA, Smith BD, Jones RJ. Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors. Br J Haematol. 2005 130 : 373 81.
231. White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC, Quinn SR, Manley PW, Hughes TP. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107):reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood. 2006 108 : 697 704.
232. Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DC, Kimura S, Ottmann OG, Druker BJ, Villunger A, Roberts AW, Strasser A. Bim and Bad mediate imatinib-induced killing of Bcr/Abl +leukaemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA. 2006 103 : 14907 12.
233. Jorgensen HG, Copland M, Allan EK, Jiang X, Eaves A, Eaves C, Holyoake TL. Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clin Cancer Res. 2006 12 : 626 33.
234. Holtz M, Forman SJ, Bhatia R. Growth factor stimulation reduces residual quiescent chronic myeloge-nous leukemia progenitors remaining after imatinib treatment. Cancer Res. 2007 67 : 1113 20.
235. Gal H, Amariglio N, Trakhtenbrot L, Jacob-Hirsh J, Margalit O, Avigdor A, Nagler A, Tavor S, Ein-Dor L, Lapidot T, Domany E, Rechavi G, Givol D. Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. Leukemia. 2006 20 : 2147 54.
236. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukaemic stem cells. Nat Med. 2006 12 : 1167 74.
237. Deshpande AJ, Cusan M, Rawat VP, Reuter H, Krause A, Pott C, Quintanilla-Martinez L, Kakadia P, Kuchenbauer F, Ahmed F, Delabesse E, Hahn M, Lichter P, Kneba M, Hiddemann W, Macintyre E, Mecucci C, Ludwig WD, Humphries RK, Bohlander SK, Feuring-Buske M, Buske C. Acute myeloid leukemia is propagated by a leukaemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. Cancer Cell. 2006 10 : 363 74.
238. Peacock CD, Wang Q, Gesell GS, Corcoran-Schwartz IM, Jones E, Kim J, Devereux WL, Rhodes JT, Huff CA, Beachy PA, Watkins DN, Matsui W. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci USA. 2007 104 : 4048 53.
239. Sims-Mourtada J, Izzo JG, Ajani J, Chao KS. Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene. 2007 26 : 5674 9.
240. Clement V, Sanchez P, de TN, Radovanovic I, Altaba A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol. 2007 17 : 165 72.
241. Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, Kerbel RS. Anticancer therapies combining antian-giogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res. 2007 67 : 3560 4.
242. Yang ZJ, Wechsler-Reya RJ. Hit 'em where they live: targeting the cancer stem cell niche. Cancer Cell. 2007 11 : 3 5.